Skip to main content

Table 2 Results

From: Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction – a prospective cohort pilot study within a randomized clinical trial

  Chemotherapy   Chemoradiotherapy   
Variable Pre neoadjuvant Post neoadjuvant P a Pre neoadjuvant Post neoadjuvant p a p b
EF (%) 59 (56–62) 57 (53–60) >0.99 60 (57–64) 59 (55–63) >0.99 0.80
GS (%) −17.6 (−16, −19) −15.7 (−14, −17) 0.26 −17.3 (−16, −19) −16.1 (−14, −18) >0.99 0.59
MAPSE sept (cm/s) 12.5 (11.5–13.5) 12.1 (11.2–13.1) >0.99 12.6 (11.4–13.8) 11.1 (10.1–12.2) 0.02 0.09
MAPSE lat (cm/s) 11.5 (10.4–12.6) 11.2 (10.2–12.3) >0.99 11.2 (10.0–12.4) 11.0 (9.8–12.1) >0.99 0.96
E (cm/s) 72.0 (62.6–81.4) 68.1 (62.2–74.1) >0.99 78.8 (68.4–89.3) 64.1 (57.2–70.9) 0.01 0.09
A (cm/s) 67.8 (58.2–77.5) 74.6 (63.9–85.3) 0.37 82.0 (71.1–92.7) 83.7 (71.6–95.9) 0.98 0.41
E/A 1.08 (0.93–1.25) 0.95 (0.81–1.10) 0.43 0.97 (0.82–1.14) 0.77 (0.65–0.92) 0.03 0.39
NT–ProBNP (ηg/l) 93 (58–149) 108 (70–167) >0.99 65 (32–130) 154 (92–260) 0.05 0.07
Exercise test (W) 150 (135–165) 133 (115–151) 0.03 151 (133–151) 118 (96–140) 0.001 0.10
  1. Data are presented as mean (95% confidence interval). aMixed models test of within-group changes; bMixed models test of interaction effect; EF, ejection fraction; GS, global strain; MAPSE, mitral annular plane systolic excursion; NT-proBNP, N-terminal pro-brain natriuretic peptide.